The Case of a Man With Two Sets of DNA Raises More Questions
A crime lab studied a patient ’s response to a bone marrow transplant. Readers requested more information about the perplexing findings.
NICE has published more “rapid” guidelines, this time covering provision of radiotherapy services and bone marrow transplant during the Covid-19 pandemic.
Early detection of Primary Immunodeficiencies Disorders (PIDDs) is of paramount importance for effective treatment and disease management. Many PIDDs would be strong candidates for newborn screening (NBS) if robust screening methods could identify patients from dried blood spots (DBS) during the neonatal period. As majority of congenital PIDDs result in the reduction or absence of specific proteins, direct quantification of these target proteins represents an attractive potential screening tool. Unfortunately, detection is often limited by the extremely low protein concentrations in blood cells and limited blood volume pre...
We have previously reported that transient mixed hematopoietic chimerism induced via donor bone marrow transplantation can achieve tolerance to cardiac allografts in non-human primates (NHPs). The purpose of this study was to measure the frequency and properties of a unique subset of CD8+ B cells, recently identified in our laboratory, in tolerant monkeys.
Alterations to the intestinal microbiome prior to bone marrow transplant (BMT) are associated with post-BMT mortality, and distinct compositional changes (increase in Firmicutes and decrease in Bacteroidetes) are present in adults with cardiovascular (CV) disease. We hypothesize that alterations to the intestinal microbiome occur in children after pediatric heart transplant (HTx).
Induction of tolerance in combined heart/kidney transplantation in non-human primates is possible by applying a mixed chimerism-based conditioning protocol which induces indefinite tolerance. However, donor brain death negatively impacts tolerance induction, leading to a higher incidence of humoral as well as cellular rejection. Here, we investigated whether delaying conditioning and donor bone marrow transplantation (DBMT) until four months after organ transplantation would diminish the detrimental effects of donor brain death and permit tolerance induction despite donor brain death.
Conclusions: Despite the various advantages of the delayed tolerance induction protocol, it failed to reliably induce mixed chimerism and thus immunologic tolerance to vascularized composite allografts, given currently available immunosuppression treatment options. Ongoing work shows promise in overcoming these limitations.
Floyd Rohan Not only do racial and ethnic minority children and adolescents with chronic illness experience disparities in health status and health outcomes, they also experience significant healthcare disparities, including differences in healthcare coverage, access to care, and quality of care. It is well known that the interaction between psychosocial functioning, health behaviors and ethnic and racial disparities, ultimately leads to worse health and psychosocial outcomes in pediatric and AYA chronic illness patient populations, including increased rates of morbidity and mortality. Investigating the impact of ra...
The American Society for Transplantation and Cellular Therapy position statement on MMR prevention in immunocompromised cancer and hematopoietic cell transplantation (HCT) patients by Pergam et. al. addresses many of the concerns both providers and patients have about Measles prevention post-transplant.1 However, we are skeptical about the data regarding the safety of the MMR vaccination guidelines for post-allogenic bone marrow transplant patients as stated in this article.
Innovation in the cancer treatment space offers great promise, but even when approved by the European Medicines Agency (EMA) and other national regulatory bodies, patients can still face protracted delays in accessing new treatments. Uncertainties in the evidence base for pioneering therapies can lead to delays from health technology assessment (HTA) agencies and payers in securing reimbursement. To accelerate progress here, HTA frameworks must evolve, says Clare Hague, Therapy Area Market Access Lead, Hematology at Janssen EMEA, speaking ahead of the upcoming eyeforpharma Barcelona 2020 confere...
Conclusion Despite multimodality therapy, high risk neuroblastoma had a propensity of treatment failure in terms of relapsed or refractory, with some objective responses after 131I-mIBG treatments. The declined or non-rising Curie score upon second post-treatment total body scan was an important predictor of survival and aided a decision whether or not to proceed with bone marrow transplantation.